India, Nov. 4 -- The Delhi high court on Wednesday issued notice in a petition seeking directions to the Centre and its drug regulatory authorities to complete the pending safety review of Ranitidine, a medication commonly used to treat acidity and reduce stomach acid, within a stipulated time frame.

A bench of acting Chief Justice Nitin Sambre and justice Sanjay Sharma sought Centre, Central Drugs Standard Control Organisation (CDSCO), Drugs Technical Advisory Board (DTAB) and Indian Council of Medical Research's (ICMR) response in a petition filed by Dr Chandresh Jain, an advocate.

In his petition, Jain contended that the safety of Ranitidine remained an unresolved concern since September 2019, when foreign drug regulators were alerte...